Post-Marketing Studies For All Products Endorsed By Drug Safety Expert
This article was originally published in The Pink Sheet Daily
Executive Summary
A mechanism is needed for post-marketing testing of all new drugs, safety expert Gross says during a Drug & Device Dialogue audio conference on the COX-2 advisory committee meeting. FDA “needs more tools” to protect public health, consumer rep Levin argues.